1. Diagnosis et prima curatione cancri pulmonis
Patientes Lu praecogniti cum pulmone adenocarcinoma et nodi metastasi lymphatici die 26 Augusti 2005. Sinistra lobectomy inferior fiebat die 22 Septembris 2005. Carboplatina cum taxotere coniuncta adhibita est 4 vicibus post chirurgicam. Die 3 Augusti 2007, ob effusionem pleuralem, diagnosis confirmata est frequentissima, et tractata cum Tarceva (numerus cyclorum ignotus est). Die VIII mensis Ianuarii anno MMVIII progressus cancer in reexaminatione inventus est et tunc curatio Tarceva cessavit et curatio Libita per XVI cyclos incepit. Eodem tempore, vertebralis metastasis coxae inventa est et 8 cyclos Zetai fiebant.
2. Primum tempus orci iudiciis participare, condicio moderata est.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the tuberculum was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. In secundo iudicio clinico, tumor manifesto evanuit.
On August 6, 2012, Mr. Lu participated in the AP26113 drug orci iudicio at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the tumorem in cerebro decreased and became large.
4. Mutationes gene raras inveniunt et in novis iudiciis clinicis participationem expectamus
Re-examen in mense Iulio 2014, totum corpus DELICIUM ostendit: Laesiones cerebri basically stabiles erant, et pectus progressus manifestum habuit. Die 12 Maii 2014, lympha suspecta anti-AP26113 (3 cellae, maxima 1.1 cm) lineae cellularum excultae factae sunt apud Massachusetts Hospitali Generali et perrexerunt AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
